Altered metabolism in head and neck squamous cell carcinoma: An opportunity for identification of novel biomarkers and drug targets

Head and Neck

Volumn 34, Issue 2, 2012, Pages 282-290

  Sandulache, Vlad C ^a,b   Myers, Jeffrey N ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINONICOTINAMIDE; ADENYLATE KINASE; BIOLOGICAL MARKER; BROMOPYRUVIC ACID; CISPLATIN; CYCLINE; DEOXYGLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; LONIDAMINE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MONOCARBOXYLATE TRANSPORTER 4; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE; PYRUVIC ACID DERIVATIVE; RAPAMYCIN; TEMSIROLIMUS; TRANSCRIPTION FACTOR FOXO; TUBERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL METABOLISM; CELL PROLIFERATION; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; METABOLISM; MOUTH CARCINOMA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TREATMENT RESPONSE; TUMOR CELL; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLYCOLYSIS; HEAD AND NECK NEOPLASMS; HUMANS; ONCOGENE PROTEIN V-AKT; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84855682374     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21664     Document Type: Review

References (82)

1. American Cancer Society. Cancer facts and figures 2009. 2009.
2. Forastiere A, Weber R, Ang K,. Treatment of head and neck cancer. N Engl J Med 2008; 358: 1076-1078.
3. Forastiere AA,. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol 2008; 97: 701-707. (Pubitemid 351812972)
4. Forastiere AA, Trotti A, Pfister DG, Grandis JR,. Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006; 24: 2603-2605. (Pubitemid 46622079)
5. Pignon JP, le Maitre A, Maillard E, Bourhis J,. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
6. Bernier J, Bentzen SM, Vermorken JB,. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009; 6: 266-277.
7. Warburg O,. On the origin of cancer cells. Science 1956; 123: 309-314.
8. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
9. Dang CV,. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010; 70: 859-862.
10. Nelson DL, Cox MM,. Lehninger principles of biochemistry, 5th ed. New York: W.H. Freeman and Co.; 2008.
11. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104: 19345-19350.
12. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008; 105: 18782-18787.
13. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y,. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007; 178: 93-105. (Pubitemid 47026405)
14. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ,. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009; 69: 7986-7993.
15. Zhao FQ, Keating AF,. Functional properties and genomics of glucose transporters. Curr Genomics 2007; 8: 113-128. (Pubitemid 46690959)
16. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT,. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046-1051. (Pubitemid 27427603)
17. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H,. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998; 11: 437-443. (Pubitemid 28224445)
18. Baer S, Casaubon L, Schwartz MR, Marcogliese A, Younes M,. Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope 2002; 112: 393-396. (Pubitemid 34135891)
19. Mathupala SP, Heese C, Pedersen PL,. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 1997; 272: 22776-22780. (Pubitemid 27386097)
20. Mathupala SP, Rempel A, Pedersen PL,. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997; 29: 339-343.
21. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233. (Pubitemid 351380249)
22. Telang S, Yalcin A, Clem AL, et al. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006; 25: 7225-7234. (Pubitemid 44809088)
23. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N,. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 2008; 32: 101-111. (Pubitemid 351176067)
24. Plas DR, Thompson CB,. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005; 24: 7435-7442. (Pubitemid 41637983)
25. Pelicano H, Martin DS, Xu RH, Huang P,. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-4646. (Pubitemid 44187614)
26. McFate T, Mohyeldin A, Lu H, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 2008; 283: 22700-22708.
27. Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, Koukourakis ML, Harris AL,. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer 2008; 98: 1975-1984. (Pubitemid 351821556)
28. Sun W, Zhou S, Chang SS, McFate T, Verma A, Califano JA,. Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15: 476-484.
29. Tong X, Zhao F, Thompson CB,. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 2009; 19: 32-37.
30. Majewski N, Nogueira V, Bhaskar P, et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004; 16: 819-830. (Pubitemid 39586539)
31. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM,. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem 2002; 277: 33895-33900.
32. Lee SS, Kennedy S, Tolonen AC, Ruvkun G,. DAF-16 target genes that control C. elegans life-span and metabolism. Science 2003; 300: 644-647. (Pubitemid 36520589)
33. Dan HC, Sun M, Yang L, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002; 277: 35364-35370.
34. Arsham AM, Howell JJ, Simon MC,. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 278: 29655-29660. (Pubitemid 36962350)
35. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G,. Mammalian TOR: a homeostatic ATP sensor. Science 2001; 294: 1102-1105. (Pubitemid 33041865)
36. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J,. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-14494. (Pubitemid 28319170)
37. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18: 283-293. (Pubitemid 41350534)
38. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
39. 2 tension. Proc Natl Acad Sci U S A 1995; 92: 5510-5514.
40. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7: 77-85. (Pubitemid 40126384)
41. Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14: 2231-2239. (Pubitemid 41418022)
42. Ullah MS, Davies AJ, Halestrap AP,. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006; 281: 9030-9037. (Pubitemid 43864615)
43. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12: 149-162. (Pubitemid 28060446)
44. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 349-353. (Pubitemid 32884281)
45. Quennet V, Yaromina A, Zips D, et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006; 81: 130-135. (Pubitemid 44780779)
46. Ziebart T, Walenta S, Kunkel M, Reichert TE, Wagner W, Mueller-Klieser W,. Metabolic and proteomic differentials in head and neck squamous cell carcinomas and normal gingival tissue. J Cancer Res Clin Oncol 2010; Apr 11 [Epub ahead of print].
47. Koukourakis G, Maravelis G, Koukouraki S, Padelakos P, Kouloulias V,. Overview of positron emission tomography chemistry: clinical and technical considerations and combination with computed tomography. J BUON 2009; 14: 575-580.
48. Stokkel MP, ten Broek FW, van Rijk PP,. The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol 1998; 34: 466-471. (Pubitemid 28546859)
49. Gourin CG, Watts TL, Williams HT, Patel VS, Bilodeau PA, Coleman TA,. Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. Laryngoscope 2008; 118: 671-675. (Pubitemid 351496777)
50. Reisser C, Eichhorn K, Herold-Mende C, Born AI, Bannasch P,. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 1999; 80: 194-198. (Pubitemid 29001721)
51. Chandan VS, Faquin WC, Wilbur DC, Khurana KK,. The utility of GLUT-1 immunolocalization in cell blocks: an adjunct to the fine needle aspiration diagnosis of cystic squamous lesions of the head and neck. Cancer 2006; 108: 124-128.
52. 18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography. Br J Oral Maxillofac Surg 2008; 46: 180-186. (Pubitemid 351337627)
53. Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003; 97: 1015-1024. (Pubitemid 36173153)
54. Estilo CL, O-charoenrat P, Talbot S, et al. Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 2009; 9: 11 (abstract).
55. Wong TS, Liu X-B, Ho AC-W, Yuen AP-W, Ng RW-M, Wei WI,. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 2008; 123: 251-257. (Pubitemid 351842007)
56. Ervens J, Fuchs H, Niemann VT, Hoffmeister B,. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer. J Craniomaxillofac Surg 2008; 36: 89-94.
57. Sun W, Liu Y, Glazer CA, et al. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 2010; 16: 857-866.
58. Volker HU, Scheich M, Schmausser B, Kammerer U, Eck M,. Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol 2007; 264: 1431-1436. (Pubitemid 350112408)
59. Clark C, Shah S, Herman-Ferdinandez L, et al. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope 2010; 120: 1159-1165.
60. Wardman P,. The importance of radiation chemistry to radiation and free radical biology (The 2008 Silvanus Thompson Memorial Lecture). Br J Radiol 2009; 82: 89-104.
61. Sedletska Y, Giraud-Panis MJ, Malinge JM,. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5: 251-265. (Pubitemid 40655276)
62. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM,. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7: 3-18. (Pubitemid 46062402)
63. Maschek G, Savaraj N, Priebe W, et al. 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31-34. (Pubitemid 38114078)
64. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR,. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007; 67: 3364-3370. (Pubitemid 46724876)
65. 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 2007; 69: 1222-1230. (Pubitemid 47625869)
66. Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E III,. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol 1989; 25: 32-36. (Pubitemid 20000795)
67. Mohanti BK, Rath GK, Anantha N, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996; 35: 103-111. (Pubitemid 26137174)
68. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005; 181: 507-514. (Pubitemid 41059520)
69. Oudard S, Carpentier A, Banu E, et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2003; 63: 81-86. (Pubitemid 36681647)
70. De Lena M, Lorusso V, Latorre A, et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 2001; 37: 364-368. (Pubitemid 32182325)
71. Ihrlund LS, Hernlund E, Khan O, Shoshan MC,. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008; 2: 94-101.
72. Colella E, Merlano M, Blengio F, et al. Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck. Eur J Cancer 1994; 30A: 928-930. (Pubitemid 24256236)
73. Magno L, Terraneo F, Bertoni F, et al. Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1994; 29: 45-55. (Pubitemid 24138864)
74. Zhang XD, Deslandes E, Villedieu M, et al. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 2006; 26: 3561-3566. (Pubitemid 44701539)
75. Varshney R, Dwarakanath B, Jain V,. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int J Radiat Biol 2005; 81: 397-408. (Pubitemid 41117010)
76. Nathan CO, Amirghahari N, Rong X, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007; 67: 2160-2168. (Pubitemid 46424235)
77. Ekshyyan O, Rong Y, Rong X, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009; 8: 2255-2265.
78. Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005; 65: 9953-9961. (Pubitemid 41541476)
79. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62: 305-313. (Pubitemid 351692089)
80. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
81. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914.
82. Wu M, Neilson A, Swift AL, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 2007; 292: C125-C136. (Pubitemid 46115126)